These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26553012)

  • 1. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
    Aouri M; Barcelo C; Ternon B; Cavassini M; Anagnostopoulos A; Yerly S; Hugues H; Vernazza P; Günthard HF; Buclin T; Telenti A; Rotger M; Decosterd LA;
    Drug Metab Dispos; 2016 Jan; 44(1):151-61. PubMed ID: 26553012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PharmGKB summary: Efavirenz pathway, pharmacokinetics.
    McDonagh EM; Lau JL; Alvarellos ML; Altman RB; Klein TE
    Pharmacogenet Genomics; 2015 Jul; 25(7):363-76. PubMed ID: 25966836
    [No Abstract]   [Full Text] [Related]  

  • 3. Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients.
    Grilo NM; Correia MJ; Sequeira C; Harjivan SG; Caixas U; Diogo LN; Marques MM; Monteiro EC; Antunes AM; Pereira SA
    Toxicol Lett; 2016 Oct; 260():28-35. PubMed ID: 27543169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
    Avery LB; VanAusdall JL; Hendrix CW; Bumpus NN
    Drug Metab Dispos; 2013 Feb; 41(2):422-9. PubMed ID: 23166317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
    Soeria-Atmadja S; Österberg E; Gustafsson LL; Dahl ML; Eriksen J; Rubin J; Navér L
    PLoS One; 2017; 12(9):e0181316. PubMed ID: 28886044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
    Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
    BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
    Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
    Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.
    Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
    Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
    PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele.
    Bordin Andriguetti N; Van Schalkwyk HK; Barratt DT; Tucci J; Pumuye P; Somogyi AA
    Clin Transl Sci; 2021 Nov; 14(6):2521-2531. PubMed ID: 34415664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.
    Winston A; Amin J; Clarke A; Else L; Amara A; Owen A; Barber T; Jessen H; Avihingsanon A; Chetchotisakd P; Khoo S; Cooper DA; Emery S; Puls R; ;
    Clin Infect Dis; 2015 Apr; 60(7):1026-32. PubMed ID: 25501988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations.
    Ayuso P; Neary M; Chiong J; Owen A
    J Antimicrob Chemother; 2019 Nov; 74(11):3281-3290. PubMed ID: 31369088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
    Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
    di Iulio J; Fayet A; Arab-Alameddine M; Rotger M; Lubomirov R; Cavassini M; Furrer H; Günthard HF; Colombo S; Csajka C; Eap CB; Decosterd LA; Telenti A;
    Pharmacogenet Genomics; 2009 Apr; 19(4):300-9. PubMed ID: 19238117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.
    Abdelhady AM; Shugg T; Thong N; Lu JB; Kreutz Y; Jaynes HA; Robarge JD; Tisdale JE; Desta Z; Overholser BR
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1206-1213. PubMed ID: 27333947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
    Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.
    Vo TT; Varghese Gupta S
    Pharmacotherapy; 2016 Dec; 36(12):1245-1254. PubMed ID: 27779789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
    Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R;
    Clin Pharmacol Ther; 2015 Oct; 98(4):406-16. PubMed ID: 26044067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial.
    Winston A; Puls R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19541. PubMed ID: 25394049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
    Reay R; Dandara C; Viljoen M; Rheeders M
    OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.